Disc Medicine, Inc. Share-based Payment Arrangement, Expense
Disc Medicine, Inc. (IRON) reported Share-based Payment Arrangement, Expense of $13.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-07-30
- Disc Medicine, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $13.95M, a 65.65% increase year-over-year.
- Disc Medicine, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $11.95M, a 87.74% increase year-over-year.
- Disc Medicine, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $10.04M, a 131.73% increase year-over-year.
- Disc Medicine, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $9.51M, a 119.62% increase year-over-year.
- Disc Medicine, Inc. share-based payment arrangement, expense for fiscal 2025 was $34.34M, a 104.22% increase from fiscal 2024.
- Disc Medicine, Inc. share-based payment arrangement, expense for fiscal 2024 was $16.82M, a 204.07% increase from fiscal 2023.
- Disc Medicine, Inc. share-based payment arrangement, expense for fiscal 2023 was $5.53M, a 164.72% increase from fiscal 2022.
- Disc Medicine, Inc. share-based payment arrangement, expense for fiscal 2022 was $2.09M, a 312.03% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $13.95M 10-Q · filed 2026-07-30 | $25.89M 10-Q · filed 2026-07-30 | $35.94M derived: sum of 3 quarters · filed 2026-07-30 | $45.45M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $11.95M 10-Q · filed 2026-05-05 | $21.99M derived: sum of 2 quarters · filed 2026-05-05 | $31.50M derived: sum of 3 quarters · filed 2026-05-05 | $39.92M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $10.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.56M derived: sum of 2 quarters · filed 2026-02-26 | $27.98M derived: sum of 3 quarters · filed 2026-07-30 | $34.34M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $9.51M 10-Q · filed 2025-11-06 | $17.93M derived: sum of 2 quarters · filed 2026-07-30 | $24.30M 10-Q · filed 2025-11-06 | $28.63M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $8.42M 10-Q · filed 2026-07-30 | $14.78M 10-Q · filed 2026-07-30 | $19.12M derived: sum of 3 quarters · filed 2026-07-30 | $23.45M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $6.36M 10-Q · filed 2026-05-05 | $10.70M derived: sum of 2 quarters · filed 2026-05-05 | $15.03M derived: sum of 3 quarters · filed 2026-05-05 | $19.12M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.67M derived: sum of 2 quarters · filed 2026-02-26 | $12.76M derived: sum of 3 quarters · filed 2026-02-26 | $16.82M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $4.33M 10-Q · filed 2025-11-06 | $8.42M derived: sum of 2 quarters · filed 2025-11-06 | $12.48M 10-Q · filed 2025-11-06 | $14.41M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $4.09M 10-Q · filed 2025-08-07 | $8.15M 10-Q · filed 2025-08-07 | $10.08M derived: sum of 3 quarters · filed 2026-02-26 | $11.35M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $4.06M 10-Q · filed 2025-05-07 | $5.99M derived: sum of 2 quarters · filed 2026-02-26 | $7.25M derived: sum of 3 quarters · filed 2026-02-26 | $8.56M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.20M derived: sum of 2 quarters · filed 2026-02-26 | $4.51M derived: sum of 3 quarters · filed 2026-02-26 | $5.53M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $1.27M 10-Q · filed 2024-11-12 | $2.58M derived: sum of 2 quarters · filed 2024-11-12 | $3.60M 10-Q · filed 2024-11-12 | $4.60M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $1.31M 10-Q · filed 2024-08-08 | $2.33M 10-Q · filed 2024-08-08 | $3.33M derived: sum of 3 quarters · filed 2024-08-08 | $3.71M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $1.02M 10-Q · filed 2024-05-09 | $2.02M derived: sum of 2 quarters · filed 2024-05-09 | $2.40M derived: sum of 3 quarters · filed 2024-05-09 | $2.78M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $993.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.38M derived: sum of 2 quarters · filed 2024-03-21 | $1.76M derived: sum of 3 quarters · filed 2024-03-21 | $2.09M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $382.00K 10-Q · filed 2023-11-09 | $941.00K 10-Q · filed 2022-11-10 | $764.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.10M 10-Q · filed 2023-11-09 | $5.27M 10-Q · filed 2022-11-10 | -$4.51M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $382.00K 10-Q · filed 2023-08-11 | $2.36M 10-Q · filed 2022-08-11 | $714.00K 10-Q · filed 2023-08-11 | $4.33M 10-Q · filed 2022-08-11 | -$4.89M derived: sum of 3 quarters · filed 2023-08-11 | -$3.23M derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | $332.00K 10-Q · filed 2023-05-15 | $1.98M 10-Q · filed 2022-05-06 | -$5.28M derived: sum of 2 quarters · filed 2023-05-15 | -$3.62M derived: sum of 3 quarters · filed 2023-05-15 | -$754.00K derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$5.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$3.95M derived: sum of 2 quarters · filed 2023-03-31 | -$1.09M derived: sum of 3 quarters · filed 2023-03-31 | $507.00K 10-K · filed 2023-03-31 | $7.79M 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $1.66M 10-Q · filed 2022-11-10 | $4.52M derived: sum of 2 quarters · filed 2022-11-10 | $6.11M 10-Q · filed 2022-11-10 | $6.70M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $2.86M 10-Q · filed 2022-08-11 | $4.46M 10-Q · filed 2022-08-11 | $5.04M derived: sum of 3 quarters · filed 2022-08-11 | $5.21M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $1.59M 10-Q · filed 2022-05-06 | $2.18M derived: sum of 2 quarters · filed 2022-05-06 | $2.34M derived: sum of 3 quarters · filed 2022-05-06 | $2.48M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $590.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $751.00K derived: sum of 2 quarters · filed 2022-03-10 | $889.00K derived: sum of 3 quarters · filed 2022-03-10 | $983.00K 10-K · filed 2022-03-10 | ||||
| 2020-09-30 | $161.00K 10-Q · filed 2021-11-15 | $299.00K derived: sum of 2 quarters · filed 2021-11-15 | $393.00K 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $138.00K 10-Q · filed 2021-08-12 | $232.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $94.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |